Table 4.

Unadjusted and adjusted odds ratios (OR) for selected predictors of lipoatrophy^a

			Model 1- NRTI-sparing vs. other regimens		Model 2- Stavudine XR vs. other regimens		Model 3- Zidovudine vs. other regimens
Covariateb	Unadjusted OR (95% CI)	P-value	Adjusted OR (95% CI)	P-value	Adjusted OR (95% CI)	P-value	Adjusted OR (95% CI)	P-value
Randomized study arm
Efavirenz	2.4 (1.2–5.4)	0.02
Lopinavir	0.9 (0.4–1.9)	0.8
Lopinavir-efavirenz	0.3 (0.1–0.9)	0.03	0.3 (0.1–0.9)	0.03
Selected NRTI
Stavudine XR	4.8 (2.0–11.6)	<0.001			5.2 (2.1–12.9)	<0.001
Zidovudine	1.5 (0.7–3.0)	0.3					1.4 (0.7–3.0)	0.3
Tenofovir	0.3 (0.1–1.1)	0.06
Baseline extremity fat (per kg increase)	1.1 (0.98–1.2)	0.13	1.1 (0.98–1.2)	0.13	1.1 (0.98–1.2)	0.13	1.1 (0.97–1.2)	0.18
mtDNA haplogroup I (vs. all others)	3.9 (1.1–14.4)	0.04	3.0 (0.8–11.4)	0.11	3.7 (0.9–14.6)	0.06	3.5 (0.9–12.9)	0.07

^aLipoatrophy defined as ≥20% extremity fat loss at 96 weeks.

^bBaseline age, CD4 T cells, HIV RNA, and sex were not significant predictors of lipoatrophy (data not shown) and were not included in adjusted models.

NRTI=nucleoside reverse transcriptase inhibitor; CI=confidence interval.